Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway

Clinical trials have shown that angiotensin II receptor blockers reduce the new onset of diabetes in hypertensives; however, the underlying mechanisms remain unknown. We investigated the effects of telmisartan on peroxisome proliferator activated receptor γ (PPAR-δ) and the adenosine monophosphate (...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Xiaoli, Luo, Zhidan, Ma, Liqun, Ma, Shuangtao, Yang, Dachun, Zhao, Zhigang, Yan, Zhencheng, He, Hongbo, Cao, Tingbing, Liu, Daoyan, Zhu, Zhiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823201/
https://www.ncbi.nlm.nih.gov/pubmed/20477906
http://dx.doi.org/10.1111/j.1582-4934.2010.01085.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823201/
https://www.ncbi.nlm.nih.gov/pubmed/20477906
http://dx.doi.org/10.1111/j.1582-4934.2010.01085.x

Ejemplares similares